{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-036246","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.321744+00:00","generated_at":"2026-06-17T16:33:11.587656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition","bullets":["Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).","Cash $65.5M at Dec 31, 2022; excludes ~$50M cash from Flame acquisition in Jan 2023.","Flame acquisition: issued ~19.8M common shares + 136.8k preferred convertible into 136.8M common shares (subject to approval).","DKN-01: Part C DisTinGuish randomized trial enrollment expected completion late 2023; Part A DeFianCe CRC study enrollment near completion.","BeiGene's option for DKN-01 in Asia expired; clinical collaboration continues for DisTinGuish Part C."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-036246","json":"https://secwatch.observer/filing/0001104659-23-036246.json","markdown":"https://secwatch.observer/filing/0001104659-23-036246.md","text":"https://secwatch.observer/filing/0001104659-23-036246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/tm2310372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T16:33:11.587656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd2e3e14d80145027bdfa1c9e2207d665a35ae68","claim":"CYPHERPUNK TECHNOLOGIES INC. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 24, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923036246/0001104659-23-036246-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}